Trials / Unknown
UnknownNCT02527733
Retinal Sensitivity in BRVO After Anti-VEGF Therapy
Retinal Sensitivity in Branch Retinal Vein Occlusion After Anti-VEGF Therapy
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Fukushima Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The efficacy of anti-vascular endothelial growth factor (VEGF) therapy for branch retinal vein occlusion (BRVO) is shown, but its effect on retinal sensitivity is not fully investigated. The purpose of this study is to compare the changes in retinal sensitivity after ranibizumab therapy or combination therapy of ranibizumab and laser photocoagulation in eyes with BRVO.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab | |
| DRUG | Ranibizumab and laser |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2017-09-01
- First posted
- 2015-08-19
- Last updated
- 2015-08-19
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02527733. Inclusion in this directory is not an endorsement.